Deutsche Bank
RVLP

Deutsche Bank’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Deutsche Bank’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-70,524
Closed -$76K – 4291
2021
Q4 		$76K Sell
70,524
-579
-0.8% -$939 ﹤0.01% 3818
2021
Q3 		$210K Buy
71,103
+18,149
+34% +$61K ﹤0.01% 3549
2021
Q2 		$159K Sell
52,954
-7,795
-13% -$23.9K ﹤0.01% 3918
2021
Q1 		$198K Buy
60,749
+41,287
+212% +$170K ﹤0.01% 3635
2020
Q4 		$80K Buy
19,462
+13,394
+221% +$77.2K ﹤0.01% 3967
2020
Q3 		$33K Buy
6,068
+547
+10% +$3.15K ﹤0.01% 4030
2020
Q2 		$37K Buy
5,521
+3,023
+121% +$14.8K ﹤0.01% 3938
2020
Q1 		$8K Sell
2,498
-5,929
-70% -$31.6K ﹤0.01% 4091
2019
Q4 		$58K Buy
8,427
+6,323
+301% +$33.7K ﹤0.01% 3902
2019
Q3 		$7K Sell
2,104
-6,669
-76% -$22.6K ﹤0.01% 4606
2019
Q2 		$31K Sell
8,773
-3,976
-31% -$13.2K ﹤0.01% 4691
2019
Q1 		$44K Sell
12,749
-1,772
-12% -$13K ﹤0.01% 4596
2018
Q4 		$111K Buy
+14,521
New +$116K ﹤0.01% 4176

Other funds holding RVLP

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWM
Marietta Wealth Management Marietta, Georgia $841M AUM 21.92% 1-Year Est. Return
TC
Titleist Capital San Antonio, Texas $427M AUM 24.17% 1-Year Est. Return

Deutsche Bank's RVLP Position: Q1 2022 in Review

Deutsche Bank sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q1 2022, closing a stake of 70,524 shares — an estimated $76K sold.

Deutsche Bank first reported a position in RVLP in Q4 2018 and held it in 13 quarters. The position peaked at $210K in Q3 2021. 36 funds tracked by Wall St. Rank hold RVLP as of Q1 2022.

  • Deutsche Bank reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • Deutsche Bank sold 70,524 RVL Pharmaceuticals plc Ordinary Shares shares in Q1 2022, an estimated $76K.
  • Deutsche Bank first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 13 quarters.
  • Deutsche Bank's RVL Pharmaceuticals plc Ordinary Shares position peaked at $210K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q1 2022.

Based on Deutsche Bank's 13F filing for Q1 2022, filed 13 May 2022.